Clinical Trial Update: Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV) in Treatment-naive Patients With Type 1 Gaucher Disease [Phase 4]

View source ↗

Summary

Phase 4 trial update on rapid intravenous infusion of velaglucerase alfa (VPRIV) in treatment-naive adults with Gaucher disease type 1.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gaucher Disease Type

Drugs mentioned

• Velaglucerase alfa (VPRIV) (velaglucerase alfa)

Snippet

Sponsor: Shaare Zedek Medical Center | Conditions: Primary Disease | Phase 4 | Status: COMPLETED